Ambrosia Biosciences Secures $16MM in Series A Financing to Advance Breakthrough Therapies for Obesity
Ambrosia Biosciences, a Boulder-based drug discovery company, has announced the successful closing of its $16 million Series A financing. This significant milestone marks a crucial step forward in the company’s mission to develop orally delivered, small molecule-based therapies targeting obesity and other metabolic disorders.
A New Chapter in Drug Discovery
The financing, led by BVF Partners and Boulder Ventures, will enable Ambrosia Biosciences to scale up its operations in Boulder, Colorado. The company is set to enhance its drug discovery programs, focusing on incretins and other class B GPCRs. This funding not only provides the financial backbone needed for growth but also validates the potential of Ambrosia’s approach in the highly competitive space of metabolic disorder treatment.
Reviving a Legacy
What makes Ambrosia Biosciences stand out is its team pedigree. Following the shutdown of the Pfizer (formerly Array BioPharma) R&D site, Ambrosia has successfully reassembled the world-class medicinal chemistry team from Array BioPharma. This group of seasoned professionals brings with them years of experience and expertise, allowing Ambrosia to tackle the challenges associated with obesity and metabolic disorders with confidence.
Kyle Lefkoff, Founding Partner at Boulder Ventures and Executive Chairman of Ambrosia, emphasized the importance of this reunion. “Array BioPharma was among the best small molecule drug discovery teams on the planet,” Lefkoff stated. He highlighted how the shutdown of Pfizer/Array provided a unique opportunity to bring this talented team back together under Ambrosia’s banner.
A Focus on Small Molecule Therapies
Ambrosia Biosciences is dedicated to developing small molecule-based therapies that can be taken orally. Unlike peptide-based treatments, small molecule therapies offer several advantages, including personalized dosing and the potential for fewer side effects. These therapies are designed to address the limitations of current treatments, such as cost and manufacturability, making them a more accessible option for patients.
Nick Traggis, President and Founder of Ambrosia, expressed his excitement about the company’s future. “While this is a very active space, there is significant science yet to be understood and plenty of opportunity to improve upon existing GLP-1 based drugs. I’m proud of the work our founding science team has already done and look forward to using this financing to scale up our drug discovery efforts.”
Impacting the Community
Ambrosia Biosciences isn’t just about innovation in drug discovery; it’s also about making a positive impact on the community. The company has managed to turn the shutdown of a major R&D site into a new beginning, providing a place for talented scientists to continue their important work. This commitment to the local community and the broader scientific field underscores Ambrosia’s dedication to its mission.
About Series A Funding
With the $16 million in Series A funding secured, Ambrosia Biosciences is well-positioned to make significant strides in the field of obesity treatment. The company’s focus on small molecule therapies, combined with the expertise of its reassembled team, sets the stage for the development of innovative solutions that could change the landscape of metabolic disorder treatment.
For more information about Ambrosia Biosciences and their groundbreaking work, visit www.ambrosiabiosciences.com.
